Table 2. Oncogene Rearrangements Versus... | American Society of Hematology

Table 2.

Oncogene Rearrangements Versus Tumor Site, Lymph Node, and Bone Marrow Involvement, and Staging

Parameter	No. of Patients	BCL2			BCL6			MYC
Parameter	No. of Patients	Tested	No.	%	Tested	No.	%	Tested	No.	%
	156	156	25	16	116	36	31	151	10	7
Presentation
Nodal	93	93	16	17^†	74	21	28^†,^1-153	89	2	2^1-153
Extranodal	45	45	2	4	29	10	36	45	7	16
GI tract	18	18	1	6^‡	10	3	30^‡	18	5	28
Others	27	27	1	4	19	7	32	27	2	7
Extensive	18	18	7	39	13	5	39^‡	17	1	6^1-155
			P = .003			P > .05			P = .01
Lymphadenopathy
Yes	123	123	24	19	91	28	31	120	7	6
No	33	33	1	3	25	8	32	31	3	10
			P = .02			P > .05			P > .05
Marrow involvement^*
Yes	33	33	4	12	21	4	19	30	1	3
No	107	107	21	20	95	32	34	104	9	9
			P > .05			P > .05			P > .05
Ann Arbor stage
I	40	40	0	0	31	10	32	38	4	11
II	41	41	11	27	29	9	31	40	3	8
III	24	24	3	13	21	8	38	24	1	4
IV	51	51	11	22	35	9	26	49	2	4
			P = .006			P > .05			P > .05

Parameter	No. of Patients	BCL2			BCL6			MYC
Parameter	No. of Patients	Tested	No.	%	Tested	No.	%	Tested	No.	%
	156	156	25	16	116	36	31	151	10	7
Presentation
Nodal	93	93	16	17^†	74	21	28^†,^1-153	89	2	2^1-153
Extranodal	45	45	2	4	29	10	36	45	7	16
GI tract	18	18	1	6^‡	10	3	30^‡	18	5	28
Others	27	27	1	4	19	7	32	27	2	7
Extensive	18	18	7	39	13	5	39^‡	17	1	6^1-155
			P = .003			P > .05			P = .01
Lymphadenopathy
Yes	123	123	24	19	91	28	31	120	7	6
No	33	33	1	3	25	8	32	31	3	10
			P = .02			P > .05			P > .05
Marrow involvement^*
Yes	33	33	4	12	21	4	19	30	1	3
No	107	107	21	20	95	32	34	104	9	9
			P > .05			P > .05			P > .05
Ann Arbor stage
I	40	40	0	0	31	10	32	38	4	11
II	41	41	11	27	29	9	31	40	3	8
III	24	24	3	13	21	8	38	24	1	4
IV	51	51	11	22	35	9	26	49	2	4
			P = .006			P > .05			P > .05

*In 16 cases, no bone marrow examined.

Two cases with simultaneous BCL2 and BCL6 rearrangements.

One case with simultaneous BCL2 and BCL6 rearrangements.

One case with simultaneous BCL6 and MYC rearrangements.

One case with simultaneous BCL6 and MYC rearrangements.